Pay in 4 interest-free payments of $5.32 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, which reduces blood sugar levels by enhancing the excretion of glucose in the urine
Additionally, the exploration of additional indications beyond diabetes, such as obesity and non-alcoholic fatty liver disease, represents a significant market expansion possibility
You do not want it
The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size
US$ 29.90
US$ 24.04
US$ 21.61
US$ 24.90
